JP2011511271A - 腫瘍原性、腫瘍進行、および処置効率の査定のためのアッセイシステム - Google Patents

腫瘍原性、腫瘍進行、および処置効率の査定のためのアッセイシステム Download PDF

Info

Publication number
JP2011511271A
JP2011511271A JP2010544460A JP2010544460A JP2011511271A JP 2011511271 A JP2011511271 A JP 2011511271A JP 2010544460 A JP2010544460 A JP 2010544460A JP 2010544460 A JP2010544460 A JP 2010544460A JP 2011511271 A JP2011511271 A JP 2011511271A
Authority
JP
Japan
Prior art keywords
protein
tissue sample
decrease
level
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010544460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511271A5 (enExample
Inventor
ニーブン ラジン ナレイン
インダシェカール パーサウド
Original Assignee
サイトテック ラブズ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイトテック ラブズ リミテッド ライアビリティ カンパニー filed Critical サイトテック ラブズ リミテッド ライアビリティ カンパニー
Publication of JP2011511271A publication Critical patent/JP2011511271A/ja
Publication of JP2011511271A5 publication Critical patent/JP2011511271A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2010544460A 2008-01-25 2009-01-26 腫瘍原性、腫瘍進行、および処置効率の査定のためのアッセイシステム Pending JP2011511271A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2357008P 2008-01-25 2008-01-25
PCT/US2009/031957 WO2009094619A1 (en) 2008-01-25 2009-01-26 Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014212941A Division JP6087888B2 (ja) 2008-01-25 2014-10-17 腫瘍原性、腫瘍進行、および処置効率の査定のためのアッセイシステム

Publications (2)

Publication Number Publication Date
JP2011511271A true JP2011511271A (ja) 2011-04-07
JP2011511271A5 JP2011511271A5 (enExample) 2013-03-07

Family

ID=40901454

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010544460A Pending JP2011511271A (ja) 2008-01-25 2009-01-26 腫瘍原性、腫瘍進行、および処置効率の査定のためのアッセイシステム
JP2014212941A Expired - Fee Related JP6087888B2 (ja) 2008-01-25 2014-10-17 腫瘍原性、腫瘍進行、および処置効率の査定のためのアッセイシステム
JP2017017265A Pending JP2017102125A (ja) 2008-01-25 2017-02-02 腫瘍原性、腫瘍進行、および処置効率の査定のためのアッセイシステム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014212941A Expired - Fee Related JP6087888B2 (ja) 2008-01-25 2014-10-17 腫瘍原性、腫瘍進行、および処置効率の査定のためのアッセイシステム
JP2017017265A Pending JP2017102125A (ja) 2008-01-25 2017-02-02 腫瘍原性、腫瘍進行、および処置効率の査定のためのアッセイシステム

Country Status (7)

Country Link
US (1) US10365279B2 (enExample)
EP (2) EP2245460B1 (enExample)
JP (3) JP2011511271A (enExample)
KR (2) KR101711860B1 (enExample)
AU (1) AU2009206289A1 (enExample)
ES (2) ES2453161T3 (enExample)
WO (1) WO2009094619A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
KR101765999B1 (ko) 2015-01-21 2017-08-08 서울대학교산학협력단 암 바이오마커의 성능 평가 장치 및 방법
CA3126432A1 (en) * 2019-02-01 2020-08-06 Health Research, Inc. Methods and compositions for treating resistant and recurrent forms of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508505A (ja) * 2001-11-09 2005-03-31 ソース・プリシジョン・メディシン・インク 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19736691A1 (de) 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
AU2002216009A1 (en) 2000-11-03 2002-05-15 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
US20030138792A1 (en) * 2001-05-31 2003-07-24 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
FR2840923B1 (fr) 2002-06-17 2007-07-06 Centre Nat Rech Scient Agent anti-resistance a l'oxaliplatine
WO2003106974A2 (en) 2002-06-18 2003-12-24 Irm Llc Diagnosis and treatment of chemoresistant tumors
EP1507148B1 (en) 2003-08-25 2005-02-23 MTM Laboratories AG Method for detecting carcinomas in a solubilized cervical body sample
CA2561513C (en) 2004-03-29 2019-02-26 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
WO2005103281A2 (en) * 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
WO2006022895A2 (en) 2004-08-02 2006-03-02 Children's Medical Center Corporation Platelet biomarkers for cancer
EP2302388A1 (en) * 2004-10-14 2011-03-30 Genentech, Inc. COP1 molecules and uses thereof
WO2007137187A2 (en) * 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508505A (ja) * 2001-11-09 2005-03-31 ソース・プリシジョン・メディシン・インク 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5010016722; ＧＡＲＣＥＡ: 'ＭＯＬＥＣＵＬＡＲ　ＰＲＯＧＮＯＳＴＩＣ　ＭＡＲＫＥＲＳ　ＩＮ　ＰＡＮＣＲＥＡＴＩＣ　ＣＡＮＣＥＲ：　Ａ　ＳＹＳＴＥＭＡＴＩＣ　ＲＥＶＩＥＷ' ＥＵＲＯＰＥＡＮ　ＪＯＵＲＮＡＬ　ＯＦ　ＣＡＮＣＥＲ Ｖ４１, 2005, Ｐ２２１３-２２３６ *
JPN6014025423; ＥＸＰＥＲＴ　ＲＥＶＩＥＷ　ＯＦ　ＭＯＬＥＣＵＬＡＲ　ＤＩＡＧＮＯＳＴＩＣＳ Ｖｏｌ．５　Ｎｏ．３, 2005, ｐ３５３-３７５ *

Also Published As

Publication number Publication date
JP2015052605A (ja) 2015-03-19
JP2017102125A (ja) 2017-06-08
EP2245460A1 (en) 2010-11-03
EP2708894A3 (en) 2014-04-02
EP2708894B1 (en) 2016-07-06
AU2009206289A1 (en) 2009-07-30
KR101711860B1 (ko) 2017-03-03
WO2009094619A1 (en) 2009-07-30
EP2245460A4 (en) 2011-05-25
EP2245460B1 (en) 2013-12-25
US20110027811A1 (en) 2011-02-03
EP2708894A2 (en) 2014-03-19
KR20100131435A (ko) 2010-12-15
ES2589506T3 (es) 2016-11-14
US10365279B2 (en) 2019-07-30
ES2453161T3 (es) 2014-04-04
KR101714359B1 (ko) 2017-03-09
HK1150401A1 (en) 2011-12-23
KR20150123344A (ko) 2015-11-03
JP6087888B2 (ja) 2017-03-01

Similar Documents

Publication Publication Date Title
JP6087888B2 (ja) 腫瘍原性、腫瘍進行、および処置効率の査定のためのアッセイシステム
Kitaya et al. Immunohistochemistrical and clinicopathological characterization of chronic endometritis
Borboroglu et al. Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy
Hinnis et al. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients
Rovin et al. The kidney biopsy in lupus nephritis: is it still relevant?
Harvell et al. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance
JP2006524315A (ja) 前立腺疾患を有する患者についての転帰を決定する方法
Yin et al. The levels of Ki-67 positive are positively associated with lymph node metastasis in invasive ductal breast cancer
de Aguiar et al. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review
Kato et al. Quality of life in active surveillance for early prostate cancer
Pu et al. Companied P16 genetic and protein status together providing useful information on the clinical outcome of urinary bladder cancer
Serra et al. Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival.
Guerra et al. Long-term impact of surgical route and tumor size on risk of recurrence among early-stage cervical cancer patients in a managed care population
Vallvé-Juanico et al. External validation of putative biomarkers in eutopic endometrium of women with endometriosis using NanoString technology
Weinekötter et al. Tissue S100/calgranulin expression and blood neutrophil-to-lymphocyte ratio (NLR) in dogs with lower urinary tract urothelial carcinoma
AU2015203304B2 (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
Lee et al. Proteomic analysis of pelvic autonomic nerve in nerve-sparing radical hysterectomy for cervical carcinoma
Udiyanto et al. A cohort study: caspase-3 as prognostic factor of radiation therapy in the advanced stage of cervical cancer (IIB-IIIB) patients
Yurtkal et al. Analyzing 10-year time trends for Hysterectomy and Oophorectomy: Focus on Endometrial sampling and risk factors for Endometrial Cancer
TWI391660B (zh) 偵測致死細胞的方法與材料及其應用
HK1150401B (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
Faridi et al. Estimation of Serum Calponin-2 in Patients With Breast Carcinoma and Its Clinicopathological Correlation
HK1195623A (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
HK1195623B (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
JP6875678B2 (ja) 粘液線維肉腫の浸潤性判定補助方法および当該方法に利用される粘液線維肉腫の浸潤性判定用キット

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130712

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131015

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140618

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20141010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141010